Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)

Market Cap	61.54B
Revenue (ttm)	928.01M
Net Income (ttm)	-301.59M
Shares Out	919.06M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,068,620
Average Volume	23,460,522
Open	67.50
Previous Close	67.61
Day's Range	65.10 - 67.68
52-Week Range	15.75 - 71.71
Beta	0.24
RSI	63.82
Earnings Date	Apr 22, 2026

About SHE:300255

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium injections, enoxaparin sodium injections, nandroparin calcium injection, dalteparin sodium API and injections, and other products. The company was found...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 1,254
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300255

Financial Performance

In 2024, SHE:300255's revenue was 1.03 billion, a decrease of -26.92% compared to the previous year's 1.41 billion. Losses were -249.48 million, -79.88% less than in 2023.